Drug Profile
Research programme: recombinant human serum albumin biosimilar - Biogenomics
Latest Information Update: 15 Oct 2021
Price :
$50
*
At a glance
- Originator Biogenomics
- Class Plasma expanders
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hypoalbuminaemia; Hypovolaemia
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Hypoalbuminaemia in India (IV, Infusion)
- 28 Feb 2018 No recent reports of development identified for research development in Hypovolaemia in India (IV, Infusion)
- 16 Jan 2014 Research programme: recombinant human serum albumin biosimilar - Biogenomics is available for licensing in World as of 16 Jan 2014. http://www.biogenomics.co.in